Evaluation of Anthracycline Effects on NT-ProBNP Plasma Level in Children with Malignancy

Authors: not saved
Abstract:

Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. Anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. We measured the plasma levels of NT-proBNP to determine whether it might serve as a simple prognostic indicator of anthracycline-induced cardiotoxicity and to estimate the toxic levels of anthracyclines in children with malignancy treated with anthracycline containing regimens in Tehran’s Mofid hospital. Materials and Methods: This study was performed as a before and after clinical trial. Twenty-nine pediatric patients less than fifteen years old with newly diagnosed cancer were enrolled in this study. All patients received anthracycline-containing chemotherapy with 120 to 150 mg/m² in accumulative dose. Serial measurements of plasma NT-proBNP levels and echocardiographies were taken before onset of chemotherapy, simultaneous with accumulative dose of 120 to 150 mg/m² and two weeks after that dose. Results: Plasma levels of NT-proBNP were within normal limits before treatment and increased significantly after the mentioned accumulative dose (P=0.002) in 26 patients out of 29. All patients had normal echocardiograms and none developed heart failure during the two-year period of the study.Conclusion: NT-proBNP levels increases significantly after 120 to 150 mg/m² as accumulative dose in a subset of pediatric cancer patients. This increase is not associated with echocardiographic or clinical evidence of cardiac dysfunction. Longer follow-up of these patients is necessary to determine whether NT-proBNP can be used as an early and prognostic marker for anthracycline-induced cardiotoxicity and whether 120 to 150 mg/m² as accumulative dose   of anthracycline is a safe dose or not.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

evaluation of anthracycline effects on nt-probnp plasma level in children with malignancy

background: nt-probnp is a marker that is released from ventricles in response to pressure and volume overload. raised plasma level of nt-probnp is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. we...

full text

The effect of amlodipine and sildenafil on the NT-proBNP level of patients with COPD-induced pulmonary hypertension.

Pulmonary hypertension (PH) is an important cause of heart failure in chronic obstructive pulmonary disease (COPD). The pro brain natriuretic peptide N-terminal (NT-proBNP) has been suggested as a noninvasive marker to evaluate ventricular function. However, there is no evidence to support the use of NT-proBNP in monitoring the benefits of vasodilators in COPD induced PH. Thus, we used NT-proBN...

full text

Usefulness of Serum NT-proBNP in Diagnosis of Generalized Seizures in Egyptian Children

  Background Seizures may occur in as many as 1% of children. The most urgent type of seizures is generalized tonic-clonic seizures (GTCS). N-terminal prohormone of brain natriuretic peptide (NT‐proBNP) has been considered as a promising biomarker in numerous acute illnesses. We aimed to evaluate usefulness of NT‐proBNP for diagnosis of g...

full text

The effect of amlodipine and sildenafil on the NT-proBNP level of patients with COPD-induced pulmonary hypertension.

Pulmonary hypertension (PH) is an important cause of heart failure in chronic obstructive pulmonary disease (COPD). The pro brain natriuretic peptide N-terminal (NT-proBNP) has been suggested as a noninvasive marker to evaluate ventricular function. However, there is no evidence to support the use of NT-proBNP in monitoring the benefits of vasodilators in COPD induced PH. Thus, we used NT-proBN...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue None

pages  33- 38

publication date 2009-10

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023